CDA | Evidence Driven
CDA | Evidence Driven

upadacitinib

Details

Files
Generic Name:
upadacitinib
Project Status:
Complete
Therapeutic Area:
Psoriatic Arthritis, adults
Manufacturer:
AbbVie
Brand Name:
Rinvoq
Project Line:
Reimbursement Review
Project Number:
SR0658-000
NOC Status at Filing:
Pre NOC
Performance Metric:
Achieved
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to, one or more DMARDs. Rinvoq may be used as monotherapy or in combination with nonbiologic DMARDs.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Rinvoq is indicated for the treatment of adults with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other DMARDs.. Rinvoq may be used as monotherapy or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs (DMARDs).
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input open27-Nov-20
Call for patient/clinician input closed29-Jan-21
Clarification:

- Patient input submission received from Arthritis Consumer Experts, Canadian Arthritis Patient Alliance and Arthritis Society, Canadian Association of Psoriasis Patients and Canadian Psoriasis Network, Canadian Spondylitis Association

Submission received04-Jan-21
Submission accepted18-Jan-21
Review initiated19-Jan-21
Draft CADTH review report(s) provided to sponsor for comment19-Apr-21
Deadline for sponsors comments28-Apr-21
CADTH responses on draft review report(s) provided to sponsor04-Jun-21
Expert committee meeting (initial)16-Jun-21
Draft recommendation issued to sponsor28-Jun-21
Draft recommendation posted for stakeholder feedback08-Jul-21
End of feedback period22-Jul-21
Final recommendation issued to sponsor and drug plans04-Aug-21
Final recommendation posted20-Aug-21
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)18-Aug-21
CADTH review report(s) posted08-Oct-21

Files

Recommendation and Reasons View PDF
Clinical and Pharmacoeconomic combined Report View PDF
Patient Group Input Submission View PDF
Stakeholder feedback on Draft Recommendation View PDF
Last Updated : October 8, 2021